Cytokine Release Syndrome
📧 Sign up to get email alerts when something new happens for Cytokine Release Syndrome.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-21EMA Authorised: Tuyory — Chemical Works of Gedeon Richter Plc. (Gedeon Richter Plc.)
EMA authorised Tuyory from Chemical Works of Gedeon Richter Plc. for multiple indications including rheumatoid arthritis, juvenile arthritis…
-
EMA approval · 2026-08-19EMA Authorised: Tyenne (tocilizumab) — Fresenius Kabi Deutschland GmbH
Tyenne (tocilizumab) has been authorised by the EMA for multiple indications including rheumatoid arthritis, cytokine release syndrome, juve…
-
EMA approval · 2026-08-13EMA Authorised: RoActemra (tocilizumab) — Roche Registration GmbH
RoActemra (tocilizumab) has been authorised by the European Medicines Agency for multiple indications including rheumatoid arthritis, juveni…
-
EMA approval · 2026-06-15EMA Authorised: Tuyory — Chemical Works of Gedeon Richter Plc. (Gedeon Richter Plc.)
Tuyory has been authorised by the EMA for multiple indications including rheumatoid arthritis, juvenile arthritis, cytokine release syndrome…
-
EMA approval · 2026-06-09EMA Authorised: Avtozma (tocilizumab) — Celltrion Healthcare Hungary Kft.
Avtozma (tocilizumab) has been authorised in the EU for rheumatoid arthritis, juvenile idiopathic arthritis, cytokine release syndrome, and …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-06-03Clinical Trial Results: Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy [Phase 2]
Phase 2 trial evaluating siltuximab for treating cytokine release syndrome and ICANS associated with CAR-T cell therapy; study completed wit…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event [NA]
ClinicalTrials.gov update describes a study on continuous temperature monitoring to detect cytokine release syndrome during immunotherapy, w…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation [Phase 1]
A Phase 1 clinical trial is evaluating ruxolitinib with and without abatacept (CTLA-4Ig) for prophylaxis of graft-versus-host disease and cy…
-
EMA approval · 2026-04-01EMA Authorised: RoActemra (tocilizumab) — Roche Registration GmbH
EMA authorised RoActemra (tocilizumab) for multiple indications, including rheumatoid arthritis, juvenile idiopathic arthritis, cytokine rel…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Early Detection of Complications During Immunotherapy for Haematological Malignancy [NA]
Clinical trial update from Rigshospitalet, Denmark on early detection of complications during immunotherapy for hematologic cancer, includin…
-
CLINICAL_TRIALS research · 2026-03-03Clinical Trial Update: Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome [EARLY_Phase 1]
Early-phase Phase 1 trial evaluating tadekinig alfa, an interleukin-18 binding protein, as rescue therapy for CAR T cell–related cytokine re…
-
EMA approval · 2026-01-26EMA Authorised: Avtozma (tocilizumab) — Celltrion Healthcare Hungary Kft.
EMA has authorized Avtozma, a tocilizumab biosimilar, for rheumatoid arthritis, juvenile idiopathic arthritis, cytokine release syndrome, an…
-
FDA approval · 2026-01-14FDA Approved: AVTOZMA — Supplemental Application (CELLTRION USA, Inc.)
FDA approves a supplemental application for AVTOZMA (tocilizumab) filed by Celltrion USA, Inc.
-
FDA approval · 2025-12-10FDA Approved: ACTEMRA — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for ACTEMRA (tocilizumab) submitted by Genentech, Inc.
-
EMA approval · 2025-10-02EMA Authorised: Tyenne (tocilizumab) — Fresenius Kabi Deutschland GmbH
EMA authorised Tyenne (tocilizumab) by Fresenius Kabi Deutschland GmbH for multiple indications, including rheumatoid arthritis, juvenile id…
-
CLINICAL_TRIALS trial_result · 2025-09-22Clinical Trial Update: Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy [Phase 2]
A Phase 2 clinical trial update notes evaluation of siltuximab for treating cytokine release syndrome (CRS) and ICANS related to CAR-T cell …
-
CLINICAL_TRIALS research · 2025-09-11Clinical Trial Update: Adjunctive Methylene Blue for Immunotherapy-related CRS and ICANS: Phase I Study [Phase 1]
Phase I study evaluating adjunctive methylene blue for immunotherapy-related cytokine release syndrome and ICANS; recruiting in China.
-
CLINICAL_TRIALS research · 2025-08-06Clinical Trial Update: A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma [Phase 2]
This is an update on a Phase II clinical trial evaluating siltuximab for preventing or treating CRS/ICANs after CAR-T therapy in patients wi…
-
CLINICAL_TRIALS trial_result · 2025-05-14Clinical Trial Update: Safety and Effectiveness of Cyclosporin in the Management of COVID19 ARDS Patients in Alexandria University Hospital [Phase 3]
A Phase 3 clinical trial evaluating safety and effectiveness of cyclosporin for managing COVID-19 acute respiratory distress syndrome has co…
-
FDA approval · 2025-05-12FDA Approved: TYENNE — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for TYENNE (tocilizumab-azg) from Fresenius Kabi USA, LLC.
-
CLINICAL_TRIALS research · 2025-05-11Clinical Trial Update: Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab [Phase 1]
A Phase 1 clinical trial is investigating prophylaxis and treatment of cytokine release syndrome with siltuximab prior to epcoritamab in non…
-
FDA approval · 2025-03-13FDA Approved: TYENNE — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for TYENNE (tocilizumab-AAZG) from Fresenius Kabi USA, LLC.
-
CLINICAL_TRIALS withdrawal · 2025-03-03Clinical Trial Update: Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM [Phase 2]
A Phase 2 trial evaluating siltuximab to prevent cytokine release syndrome in patients with relapsed/refractory multiple myeloma treated wit…
-
CLINICAL_TRIALS trial_result · 2024-03-26Clinical Trial Update: A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy [Phase 2]
Phase 2 trial evaluating itacitinib for prevention of cytokine release syndrome in patients undergoing immune effector cell therapy has comp…
-
CLINICAL_TRIALS trial_result · 2023-03-03Clinical Trial Update: Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome [Phase 2]
Phase 2 clinical trial update on using calcifediol for prevention and treatment of COVID-19 induced acute respiratory syndrome; trial comple…